Olivier Fedeli
Olivier Fedeli joined Sanofi R&D as NMR expert in late 1991. 2 years later, in 1993, he obtained a Ph.D. in chemistry from the University of PARIS XI-ORSAY. During about 13 years, he participated actively to support structural identification of organic compounds using NMR technologies. During this period, he was involved in the implementation of multidimensional NMR approaches, as well as hyphenated techniques such as HPLC-NMR or HPLC-SPE-NMR. In 2006, he joined a (DMPK team (Discovery Metabolism&PharmacoKintetic) to provide an expert analytical support using HPLC-MS techniques. 3 years later, he was nominated as the manager of the bioanalytical (Mass Spectrometry) discovery laboratory and participated to the implementation of this activity in a new R&D platform in Montpellier. During this period, he gained knowledge and experience in ADME (Absorption, Distribution, Metalolism and Elimination) and Tox discovery support. In 2011, he became the manager of a largest bioanalytical group supporting Discovery, as well as Clinical field. During 2012, he was put in charge of the Bioanalysis and Metabolism laboratories (Discovery and Clinical support). During this period, as he managed activities supporting development field, he increased his skills in GLP environment, as well as in in clinical support. In 2014, he got a new position as Head of Drug Disposition department (40 people: managers, scientific experts and technicians). In this domain, he managed different activities/laboratories: Bioanalysis (Mass spectrometry), PharmacoKinetics, Modeling&Simulation and Enzymologie&Metabolism. Since 2016, he is the Head of the Biomarkers and Clinical Bioanalyses department in Montpellier (about 40 people: managers, scientific experts and technicians). steering several activities/laboratories: Bioanalysis (Mass Spectrometry and Ligand Binding Aassay), ADME (in vitro models, metabolism assessment) and Immunology (Flow Cytometry). These activities are supporting mainly clinical trials in a GCLP (Good Clinical Laboratory Practices) environment, starting from FIH (First In Human) to dossier submission. Within Sanofi, he is also at the moment member of the Sanofi Montpellier R&D site steering committee, as well as the French R&D Hub Leadership team.